| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9954463 | Lung Cancer | 2018 | 33 Pages |
Abstract
Based on a threshold of GDP per capita per QALY gained (i.e. US$30,000), LDCT screening for lung cancer is unlikely to be cost-effective in New Zealand for any sociodemographic group.
Keywords
NLSTPLCOLDCTGBDDisability weightICERQALYCEACCXRCost-effectivenesschest X-rayUnited States of AmericaGlobal burden of diseaseSurveillance, Epidemiology, and End Results ProgramGross domestic productGDPLow-dose computed tomographyWorld Health OrganizationLung cancerSEERQuality-adjusted life-yearScreeningUncertainty intervalNational lung screening trialincremental cost effectiveness ratioNew ZealandWHO
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Richard Jaine, Giorgi Kvizhinadze, Nisha Nair, Tony Blakely,